16 e-Letters

published between 2009 and 2012

  • What is 'transparent' EBM?
    Huw Llewelyn

    Dear Editor,

    Different individuals have adapted and adopted the principles of EBM to different degrees and in vastly different ways [1]. There is yet another approach to EBM, which goes back a long way in terms of verbal justification on ward rounds but which has not been put in writing and taught in that way until recently [2]. It involves specifying the 'evidence' obtained from the patient that was used for ea...

    Show More
  • Editor's reply to "Conflicts of Interest"
    Richard Saitz

    I agree with Dr. Tomedi's assertion that one might question the credibility of a commentary written by someone who has received pharmaceutical industry support, or for a number of other reasons. It is for this reason that BMJ Group policies ask authors to acknowledge and openly state any competing interests (1), and as a result of this policy, Dr. Tomedi could become aware of them and consider them in reading the commenta...

    Show More
  • Conflicts of interest
    Angelo Tomedi

    Dear editor,

    The important influence of pharmaceutical manufacturers on the medical literature, and the positive "spin" placed on results and conclusions, has been well documented. Given this pervasive problem, readers may question the credibility of the commentary of an EBM reviewer who has "received consulting fees from MSD, Schering, Novartis and GSK and received honoraria from Altana, Astra Zeneca, Boehringer Inglehi...

    Show More
  • Is Rosiglitazone a safe drug?
    Chris Williams

    Dear Editor,

    I was surprised to see the assertion by Philip Home that rosiglitazone is a "particularly safe drug." Given its withdrawal from public use (the current prescribing ban recommended by MHRA in the UK, the European Medicines Agency and the FDA in the United States) due to concerns over increased cardiovascular risks, it would seem that our health authorities see it as anything but a safe drug.

  • Re:This commentary could be more helpful to me: Editors Note...
    Richard Saitz

    We are making some changes going forward to the Commentaries such that they are more structured and contain key features related to critical appraisal of the evidence: http://ebm.bmj.com/content/15/4/103.full. Some of what Dr. Bossano refers to (e.g. the use of absolute versus relative risks will be addressed by such changes.


    Richard Saitz, Editor.

    Conflict of Interest:

    Show More
  • This commentary could be more helpful to me:
    Davud Bossano
    Dear Editor

    It's quite a while since I read EBM but I received an eTOC today and was pleased to discover I could read it via my NHS Athens login. I couple of abstracts caught my including this one, because as a GP, LUTS and concern about PSA are relatively commonly seen. The commentary seemed to have a lot of detail about prostate disease, which was interesting but perhaps not entirely relevant to the paper it was comm...

    Show More